Literature DB >> 17278152

Ifosfamide neuropsychiatric toxicity in patients with cancer.

Yesne Alici-Evcimen1, William S Breitbart.   

Abstract

Ifosfamide is a chemotherapy agent commonly used in the treatment of several solid tumors and hematologic malignancies. Common ifosfamide toxicities are bone marrow suppression, alopecia, nausea and vomiting. Less common, but striking, are the rare but dramatic neuropsychiatric toxicities with discrete neurological symptoms and delirium. We report here a case of ifosfamide neuropsychiatric toxicity which presented with an isolated psychotic disorder with delusions, and was successfully treated with methylene blue. Current literature on treatment and prophylaxis of this clinically challenging chemotherapy-induced complication is presented. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278152     DOI: 10.1002/pon.1161

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  12 in total

Review 1.  From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.

Authors:  Donovan Tucker; Yujiao Lu; Quanguang Zhang
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

2.  Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases.

Authors:  You-Jung Shin; Ji-Young Kim; Jei-Won Moon; Rae-Mi You; Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Cancer Res Treat       Date:  2011-12-27       Impact factor: 4.679

Review 3.  [Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].

Authors:  Anton Schmick; Josef Jenewein; Sönke Böttger
Journal:  Neuropsychiatr       Date:  2018-01-11

Review 4.  The Intersection of Palliative Care and Interventional Radiology: Enhancing Understanding and Collaboration.

Authors:  Mary K Buss
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 5.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

Review 6.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

7.  PharmGKB summary: methylene blue pathway.

Authors:  Ellen M McDonagh; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

Review 8.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

9.  Methylene blue: revisited.

Authors:  Prashant R Ginimuge; S D Jyothi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2010-10

10.  Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Mohamed M Hafez; Meshan Lafi Aldelemy; Abdulaziz M Aleisa; Salem S Al-Rejaie; Khaled A Al-Hosaini; Naif O Al-Harbi; Mohamed M Al-Harbi; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2012-11-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.